These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 28357715)
1. No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide. de la Peña A; Cui X; Geiser J; Loghin C Clin Pharmacokinet; 2017 Nov; 56(11):1415-1427. PubMed ID: 28357715 [TBL] [Abstract][Full Text] [Related]
2. Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. Hausner H; Derving Karsbøl J; Holst AG; Jacobsen JB; Wagner FD; Golor G; Anderson TW Clin Pharmacokinet; 2017 Nov; 56(11):1391-1401. PubMed ID: 28349387 [TBL] [Abstract][Full Text] [Related]
3. Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials. Bogman K; Brumm J; Hofmann C; Giraudon M; Niggli M; Sturm-Pellanda C; Sauter A; Sturm S; Mangold B; Schmitt C Clin Pharmacokinet; 2019 Sep; 58(9):1205-1214. PubMed ID: 30968335 [TBL] [Abstract][Full Text] [Related]
4. Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive. Bush M; Scott R; Watanalumlerd P; Zhi H; Lewis E Postgrad Med; 2012 Nov; 124(6):55-72. PubMed ID: 23322139 [TBL] [Abstract][Full Text] [Related]
5. Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects. Bækdal TA; Borregaard J; Hansen CW; Thomsen M; Anderson TW Clin Pharmacokinet; 2019 Sep; 58(9):1193-1203. PubMed ID: 30945118 [TBL] [Abstract][Full Text] [Related]
6. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants. Devineni D; Manitpisitkul P; Vaccaro N; Bernard A; Skee D; Mamidi RN; Tian H; Weiner S; Stieltjes H; Sha S; Rothenberg P Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427 [TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials. Geiser JS; Heathman MA; Cui X; Martin J; Loghin C; Chien JY; de la Peña A Clin Pharmacokinet; 2016 May; 55(5):625-34. PubMed ID: 26507721 [TBL] [Abstract][Full Text] [Related]
8. EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM. Davidson JA; Manghi FP; Yu M; Linetzky B; Landó LF Endocr Pract; 2016 Dec; 22(12):1406-1414. PubMed ID: 27540883 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives. Groen-Wijnberg M; van Dijk J; Krauwinkel W; Kerbusch V; Meijer J; Tretter R; Zhang W; van Gelderen M Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):417-429. PubMed ID: 27350625 [TBL] [Abstract][Full Text] [Related]
10. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5). Skrivanek Z; Gaydos BL; Chien JY; Geiger MJ; Heathman MA; Berry S; Anderson JH; Forst T; Milicevic Z; Berry D Diabetes Obes Metab; 2014 Aug; 16(8):748-56. PubMed ID: 24762094 [TBL] [Abstract][Full Text] [Related]
11. Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion. de la Peña A; Loghin C; Cui X; Zhang X; Kapitza C; Kelly RP Diabetes Obes Metab; 2017 Apr; 19(4):517-523. PubMed ID: 27976833 [TBL] [Abstract][Full Text] [Related]
12. An Investigative Study of Pancreatic Exocrine Biomarkers, Histology, and Histomorphometry in Male Zucker Diabetic Fatty (ZDF) Rats Given Dulaglutide by Subcutaneous Injection Twice Weekly for 13 Weeks. Usborne A; Byrd RA; Meehan J; Blackbourne JL; Sullivan J; Poitout-Belissent F; Prefontaine A; Martin JA; Vahle JL Toxicol Pathol; 2015 Dec; 43(8):1093-102. PubMed ID: 26269615 [TBL] [Abstract][Full Text] [Related]
13. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide. Milicevic Z; Anglin G; Harper K; Konrad RJ; Skrivanek Z; Glaesner W; Karanikas CA; Mace K Diabetes Obes Metab; 2016 May; 18(5):533-6. PubMed ID: 26847401 [TBL] [Abstract][Full Text] [Related]
14. Dulaglutide for the treatment of type 2 diabetes. Scheen AJ Expert Opin Biol Ther; 2017 Apr; 17(4):485-496. PubMed ID: 28274140 [TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Yu M; Van Brunt K; Varnado OJ; Boye KS Diabetes Obes Metab; 2016 Apr; 18(4):419-24. PubMed ID: 26691396 [TBL] [Abstract][Full Text] [Related]
16. [Pharmacological profile and clinical trial results of a long-acting, once weekly human GLP-1 receptor agonist Dulaglutide (Genetical Recombination)]. Tamaki C; Takeuchi M; Iwamoto N; Glaesner W Nihon Yakurigaku Zasshi; 2015 Oct; 146(4):215-24. PubMed ID: 26656966 [No Abstract] [Full Text] [Related]